FIGURE 1 Clinical endpoints in the German Hepatitis C Registry. Elevated liver enzymes (ALT, ALT according to AASLD criteria, and GGT) at 24 weeks after HCV therapy were tested for their predictive value regarding clinical endpoints. Kaplan‐Meier curves demonstrating the rate of (A) hepatic decompensation, (B)  de novo  hepatocellular carcinoma, and (C) death in patients infected with HCV (n = 6982) that had undergone direct‐acting antiviral therapy. AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; GGT, gamma‐glutamyltransferase; HCV, hepatitis C virus; SVR24, sustained virologic response at 24 weeks.